



**INVESTOR CONFERENCE CALL INVITE**

**Q3 FY 2018-19**

**Syngene's Q3 FY2019 Results Conference Call**

**At 3:00 pm IST on 23th Jan, 2019**

The management team of Syngene International Limited ("Syngene") will organize a **conference call for Analysts and Investors on Wednesday, 23rd January at 3:00 pm IST** following the announcement of financial results for the quarter ended December 31, 2018.

The call will be initiated with a brief management discussion on the Q3 FY2019 performance followed by an interactive Question & Answer session. Mr. Jonathan Hunt, Chief Executive Officer and other members of the senior management team will represent Syngene on the conference call.

Details of the conference call are as under:

<b>Date:</b>	Wednesday, 23 <sup>rd</sup> Jan 2019
<b>Time:</b>	3:00 pm to 4:00 pm IST
<b>Dial-in Numbers:</b>	
Primary Number	+91 22 6280 1279 / +91 22 7115 8180
Local Access Number	+91 70 4567 1221: Available all over India (Accessible from all carriers.)
International Toll Free Numbers	<ul style="list-style-type: none"> <li>• USA – 18667462133/+13233868721</li> <li>• UK – 08081011573/+442034785524</li> <li>• Singapore – 8001012045/+6531575746</li> <li>• Hong Kong – 800964448/+85230186877</li> </ul>

## INVESTOR CONFERENCE CALL INVITE

Q3 FY 2018-19

<p>Pre-registration Facility</p>	<p>Step 1: Pre-register <a href="#">here</a>. You will receive a passcode and a pin for the call on the registered email address.</p> <p>Step 2: Dial into the call on the Conference Call date, enter the passcode &amp; pin as prompted. You will be directly connected to the call</p>
<p>Replay Facility</p>	<p>Dial in numbers: +91 22 7194 5757 / +91 22 6663 5757</p> <p>Playback ID: 67499</p> <p>The replay facility will be available from 23<sup>rd</sup> January 2019 till 04<sup>th</sup> February 2019</p>
<p>Conference Call Transcript</p>	<p>Will be available within 7 working days of the call on the corporate website: <a href="http://www.syngeneintl.com">www.syngeneintl.com</a></p>

### About Syngene

Syngene International Ltd. (**BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022**), is a global integrated discovery and development service provider for small and large molecules, Antibody-Drug Conjugates and Oligonucleotides. The Company is committed to creating strong customer impact through its cutting edge scientific capabilities and state-of-the art research and manufacturing infrastructure. It's clientele of over 300 clients span the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemicals industries and include market leaders like Bristol-Myers Squib, Baxter, Amgen, GSK, Zoetis, Merck KGaA and Herbalife. Syngene's innovation driven culture, strong team of over 3500 scientists and world-class research and manufacturing infrastructure help its clients improve R&D productivity while reducing the development time and cost. For more details, visit [www.syngeneintl.com](http://www.syngeneintl.com).

### For further information, please contact:

Chanderlekha Nayar  
 Syngene International  
 ☎: +91 80 6775 8821 | Fax: +91 80 2852 3423  
 ✉: [Chanderlekha.Nayar@syngeneintl.com](mailto:Chanderlekha.Nayar@syngeneintl.com)

**Disclaimer:** Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.